JP2022513159A - Rnaを調節する方法 - Google Patents
Rnaを調節する方法 Download PDFInfo
- Publication number
- JP2022513159A JP2022513159A JP2021530978A JP2021530978A JP2022513159A JP 2022513159 A JP2022513159 A JP 2022513159A JP 2021530978 A JP2021530978 A JP 2021530978A JP 2021530978 A JP2021530978 A JP 2021530978A JP 2022513159 A JP2022513159 A JP 2022513159A
- Authority
- JP
- Japan
- Prior art keywords
- rna
- sequence
- polypeptide
- target
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862772907P | 2018-11-29 | 2018-11-29 | |
| US62/772,907 | 2018-11-29 | ||
| US201862778361P | 2018-12-12 | 2018-12-12 | |
| US62/778,361 | 2018-12-12 | ||
| US201862780442P | 2018-12-17 | 2018-12-17 | |
| US62/780,442 | 2018-12-17 | ||
| PCT/US2019/063798 WO2020113135A1 (en) | 2018-11-29 | 2019-11-27 | Methods of modulating rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513159A true JP2022513159A (ja) | 2022-02-07 |
| JP2022513159A5 JP2022513159A5 (cg-RX-API-DMAC10.html) | 2022-12-08 |
Family
ID=68966069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530978A Pending JP2022513159A (ja) | 2018-11-29 | 2019-11-27 | Rnaを調節する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220024999A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3887516A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022513159A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113454216A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020113135A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049075A1 (en) | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068627A1 (en) * | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| WO2017220751A1 (en) * | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018017144A1 (en) * | 2016-07-19 | 2018-01-25 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| WO2018049073A1 (en) * | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| WO2018053037A1 (en) * | 2016-09-13 | 2018-03-22 | The Jackson Laboratory | Targeted enhanced dna demethylation |
| WO2018161032A1 (en) * | 2017-03-03 | 2018-09-07 | The Regents Of The University Of California | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES |
| WO2018160908A1 (en) * | 2017-03-03 | 2018-09-07 | Flagship Pioneering, Inc. | Methods and systems for modifying dna |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| CA2137297C (en) | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Reactive vesicle and functional substance-fixed vesicle |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| JP4335310B2 (ja) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用 |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| ES2728782T3 (es) * | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US10330674B2 (en) | 2015-01-13 | 2019-06-25 | Massachusetts Institute Of Technology | Pumilio domain-based modular protein architecture for RNA binding |
-
2019
- 2019-11-27 WO PCT/US2019/063798 patent/WO2020113135A1/en not_active Ceased
- 2019-11-27 EP EP19824133.3A patent/EP3887516A1/en not_active Withdrawn
- 2019-11-27 CN CN201980078727.2A patent/CN113454216A/zh active Pending
- 2019-11-27 JP JP2021530978A patent/JP2022513159A/ja active Pending
- 2019-11-27 US US17/298,317 patent/US20220024999A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068627A1 (en) * | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| WO2017220751A1 (en) * | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018017144A1 (en) * | 2016-07-19 | 2018-01-25 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| WO2018049073A1 (en) * | 2016-09-07 | 2018-03-15 | Flagship Pioneering, Inc. | Methods and compositions for modulating gene expression |
| WO2018053037A1 (en) * | 2016-09-13 | 2018-03-22 | The Jackson Laboratory | Targeted enhanced dna demethylation |
| WO2018161032A1 (en) * | 2017-03-03 | 2018-09-07 | The Regents Of The University Of California | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES |
| WO2018160908A1 (en) * | 2017-03-03 | 2018-09-07 | Flagship Pioneering, Inc. | Methods and systems for modifying dna |
Non-Patent Citations (2)
| Title |
|---|
| YANG WANG ET AL., FEBS JOURNAL, vol. 280, JPN6023044153, 2013, pages 3755 - 3767, ISSN: 0005327356 * |
| YONG LIU ET AL., PNAS, vol. 97, no. 23, JPN6023044152, 2000, pages 12541 - 12546, ISSN: 0005327357 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020113135A1 (en) | 2020-06-04 |
| CN113454216A (zh) | 2021-09-28 |
| US20220024999A1 (en) | 2022-01-27 |
| EP3887516A1 (en) | 2021-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250304976A1 (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| US20230158126A1 (en) | Rna for treatment or prophylaxis of a liver disease | |
| JP7700101B2 (ja) | 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 | |
| EP3526323B1 (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| JP2024003220A (ja) | 修飾型閉端dna(cedna)を使用する遺伝子編集 | |
| AU2009236219B2 (en) | Silencing of CSN5 gene expression using interfering RNA | |
| KR20250035055A (ko) | Pcsk9의 표적화를 위한 조성물 및 방법 | |
| CA3131130A1 (en) | Non-active lipid nanoparticles with non-viral, capsid free dna | |
| US20220133768A1 (en) | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) | |
| EP3445375A1 (en) | Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four | |
| TW202444921A (zh) | 用於靶向lpa之組合物及方法 | |
| KR20250151437A (ko) | 변형된 우라실을 포함하는 dna 조성물 | |
| EP3704238A1 (en) | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a | |
| US20220024999A1 (en) | Methods of modulating rna | |
| WO2025166323A2 (en) | Crispr-related methods and compositions targeting lipoprotein (a) expression | |
| WO2023024230A1 (zh) | 一种含有C/EBPα-saRNA的组合物 | |
| WO2023225471A2 (en) | Helitron compositions and methods | |
| WO2026102260A1 (en) | Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3) | |
| KR20260046119A (ko) | 단방향 유전자 삽입 동안 도입유전자 발현을 증진시키는 bGH-SV40L 직렬 PolyA의 용도 | |
| EA048535B1 (ru) | Композиции и способы, содержащие гидовую рнк ttr и полинуклеотид, кодирующий днк-связывающий агент, гидируемый рнк | |
| HK40006308B (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| HK40006308A (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210819 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20210819 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240521 |